✦ LIBER ✦

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

✍ Scribed by Clotet, Bonaventura; Feinberg, Judith; van Lunzen, Jan; Khuong-Josses, Marie-Aude; Antinori, Andrea; Dumitru, Irina; Pokrovskiy, Vadim; Fehr, Jan; Ortiz, Roberto; Saag, Michael; Harris, Julia; Brennan, Clare; Fujiwara, Tamio; Min, Sherene

Book ID: 122154659
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 328 KB
Volume: 383
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(14)60084-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily dolutegravir versus raltegrav

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

✍ Raffi, Francois; Rachlis, Anita; Stellbrink, Hans-Jürgen; Hardy, W David; Torti, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 368 KB

Once-daily dolutegravir versus twice-dai

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

✍ Raffi, François; Jaeger, Hans; Quiros-Roldan, Eugenia; Albrecht, Helmut; Belonos 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 274 KB

Once daily dolutegravir (S/GSK1349572) i

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

✍ Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; B 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 204 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB

Once-daily atazanavir/ritonavir versus t

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetcho 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 246 KB